Caribou Biosciences (CRBU) Current Deferred Revenue (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Current Deferred Revenue data on file, last reported at $2.6 million in Q1 2026.

• On a quarterly basis, Current Deferred Revenue fell 6.61% year-over-year to $2.6 million in Q1 2026; TTM through Mar 2026 was $2.6 million, a 6.61% decrease from a year earlier, with the FY2025 full-year figure at $1.9 million, down 39.44% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $2.6 million, up from $1.9 million in the prior quarter.
• Over the last five years, Current Deferred Revenue for CRBU reached as high as $31.1 million in Q2 2023 and fell as low as $1.9 million in Q4 2025.
• Historically, Current Deferred Revenue has averaged $8.8 million across 5 years, with a median of $6.8 million in 2024.
• Across the five-year window, Current Deferred Revenue jumped 25184.0% in 2022 and sank 89.0% in 2023, its largest moves.
• Year by year, Current Deferred Revenue stood at $25.9 million in 2022, then sank by 89.0% to $2.8 million in 2023, then climbed by 9.91% to $3.1 million in 2024, then slumped by 39.44% to $1.9 million in 2025, then jumped by 39.42% to $2.6 million in 2026.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $2.6 million in Q1 2026, $1.9 million in Q4 2025, and $2.2 million in Q3 2025.